Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-4: KarXT for Psychosis Associated with Alzheimer’s Disease
2024-516363-92-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) comparing KarXT with Placebo (2 arms). Primary endpoint: Change from baseline to end of treatment in NPI-C: H+D score. Planned start Apr 2025; status: authorised.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on 2024-516363-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516363-92-00.